Download PDF
Exp Clin Endocrinol Diabetes 2019; 127(S 01): S27-S38
DOI: 10.1055/a-0984-5696
German Diabetes Association: Clinical Practice Guidelines
© Georg Thieme Verlag KG Stuttgart · New York

Therapy of Type 1 Diabetes

Abridged Version of the S3 Guideline (AWMF Register Number: 057–013; 2nd Edition)
Thomas Haak
1   Diabetes Clinic, Bad Mergentheim, Germany
,
Stefan Gölz
2   Diabetic Practice, Esslingen, Germany
,
Andreas Fritsche
3   Internal Medicine IV, Medical Clinic, University Hospital, Tübingen, Germany
,
Martin Füchtenbusch
4   Diabetes Center, Munich, Germany
,
Thorsten Siegmund
5   Isar Clinic, Munich, Germany
,
Elisabeth Schnellbächer
6   Birkenfeld, Germany
,
Harald H. Klein
7   Medical University Hospital I - General Internal Medicine, Endocrinology and Diabetology, Gastroenterology and Hepatology, Bergmannsheil, Germany
,
Til Uebel
8   prima-diab Practice Dres. Uebel, Ittlingen, Germany
,
Diana Droßel
9   Eschweiler, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2019 (online)

Also available at
   Permissions and Reprints

Addressees and Objectives

This guideline is directed at all people with type 1 diabetes and all occupational groups that care for people with type 1 diabetes, especially:

  • Registered diabetologists,

  • General practitioners and internists,

  • Doctors working in hospitals (diabetes specialists, anaesthesiologists, surgeons, radiologists),

  • Nurses/professional caregivers (in the operating theatre and/or wards or in the field of diagnostics) and

  • Outpatient or inpatient diabetes consultants and other professional groups in diabetology.

In addition, the guideline is directed at higher-level institutions such as health insurance companies or medical services.

In preparing and updating these guidelines, the authors pursue the following objectives:

  1. Reduce the rate of diabetes-associated complications and diabetes-associated secondary damage. The diagnosis and treatment of lipodystrophy is also described for the first time;

  2. Improve the quality of life of people with type 1 diabetes;

  3. Contribute to the adequate care of people with type 1 diabetes in hospitals, both in regular and intensive care units. In particular, the implementation of safe protocols to protect against hypoglycaemia in intravenous insulin therapy should be supported;

  4. Ensure correct treatment of acute complications and thus reduce the risk of complications due to treatment;

  5. Reinforce the correct training of people with type 1 diabetes, especially in the outpatient sector.

1 This classification is based on recommendations of the American Diabetic Association (ADA).


2 The presence of diabetic ketoacidosis is defined by different international blood glucose limit values. The limit value of 250 mg/dl (13.9 mmol/l) is based on the consensus of the author group. Since the clinical effects of high blood glucose levels can vary strongly, blood glucose levels should be assessed on the basis of the clinical picture. A single blood glucose measurement of more than 250 mg/dl (13.9 mmol/l) without corresponding accompanying parameters is not yet a ketoacidosis.


 

  • References

  • 1 American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care 2017; 40 (Suppl. 1) S11-S24. doi: 10.2337/dc17-S005 LEVEL IV
    CrossrefPubMedGoogle Scholar
  • 2 Johnson DD, Palumbo PJ, Chu CP. Diabetic ketoacidosis in a community- based population. Mayo Clin Proc 1980; 55: 83-88. EK III
    PubMedGoogle Scholar
  • 3 Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2: 1279-1283 EK III
    PubMedGoogle Scholar
  • 4 Palmer JP, Asplin CM, Clemons P. et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337-1339 EK III
    CrossrefPubMedGoogle Scholar
  • 5 Wiest-Ladenburger U, Hartmann R, Hartmann U. et al. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes 1997; 46: 565-571 EK III
    CrossrefPubMedGoogle Scholar
  • 6 Bingley PJ, Bonifacio E, Mueller PW. Diabetes antibody standardization program: First assay proficiency evaluation. Diabetes 2003; 52: 1128-1136. EK III
    CrossrefPubMedGoogle Scholar
  • 7 Törn C, Mueller PW, Schlosser M. et al. Diabetes antibody standardization program: Evaluation of assays for autoantibodies to glutamic acid decar- boxylase and islet antigen-2. Diabetologia 2008; 51: 846-852. EK III
    CrossrefPubMedGoogle Scholar
  • 8 Schlosser M, Mueller PW, Torn C. et al. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010; 53: 2611-2620. EK III
    CrossrefPubMedGoogle Scholar
  • 9 Imagawa A, Hanafusa T, Miyagawa J. et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000; 342: 301-307. EK III
    CrossrefPubMedGoogle Scholar
  • 10 National Institute for Health and Clinical Excellence Type 1 diabetes in adults: Diagnosis and management. 2015; EK IV
    PubMed
  • 11 American Diabetes Association. Standards of Medical Care in Diabetes – 2017. Diabetes Care 2017; 40: 01 level IV
    CrossrefPubMedGoogle Scholar
  • 12 DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin- dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986. EK Ib
    CrossrefPubMedGoogle Scholar
  • 13 Fanelli CG, Epifano L, Rambotti AM. et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42: 1683-1689. EK IIb
    CrossrefPubMedGoogle Scholar
  • 14 Fritsche A, Stefan N, Haring H. et al. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001; 134: 729-736. EK IIb
    PubMedGoogle Scholar
  • 15 German Diabetes Society S2k guideline Diagnostics, therapy and follow-up of diabetes mellitus in old age. Registered guideline in development; On the Internet: http://www.awmf.org/leitlinien/detail/ registration/1/ll/057-017.html. LEVEL IV
    PubMed
  • 16 Lipska KJ, Hirsch IB, Riddle MC. Human insulin for type 2 diabetes: An effective, less-expensive option. JAMA 2017; 318: 23-24. doi: 10.1001/jama.2017.6939. EK IV/LoE 4
    CrossrefPubMedGoogle Scholar
  • 17 Lucidi P, Porcellati F, Marinelli Andreoli A. et al. Pharmacokinetics and pharmacodynamics of nph insulin in type 1 diabetes: The importance of appropriate resuspension before subcutaneous injection. Diabetes Care 2015; 38: 2204-2210 doi: 10.2337/dc15-0801. EK IV
    CrossrefPubMedGoogle Scholar
  • 18 Wutte A, Plank J, Sinner F. Dose-response relationship and within-sub- ject variability of insulin detemir and NPH insulin in subjects with type 1 diabetes. Diabetes 2004; 53 (Suppl. 2) A152. EK IV
    CrossrefPubMedGoogle Scholar
  • 19 Becker RHA, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47: 7-20 doi: 10.2165/00003088-200847010-00002. EK III
    CrossrefPubMedGoogle Scholar
  • 20 Weyer C, Heise T, Heinemann L. Insulin Aspart in a 30/70 Premixed Formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20: 1612-1614. doi: 10.2337/diacare.20.10.1612. EK III
    CrossrefPubMedGoogle Scholar
  • 21 Woodworth JR, Howey DC, Bowsher RR. et al. Comparative pharmaco- kinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures. Diabetes Care 1994; 17: 366-371. EK II
    CrossrefPubMedGoogle Scholar
  • 22 Heise T, Hövelmann U, Nosek L. et al. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol 2015; 11: 1193-1201. doi: 10.1517/17425255.2015.1058779. EK III
    CrossrefPubMedGoogle Scholar
  • 23 Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014; 53: 787-800. doi: 10.1007/s40262-014-0165-y. EK I
    CrossrefPubMedGoogle Scholar
  • 24 Nosek L, Coester HV, Roepstorff C. et al. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region. Clin Drug In- vestig 2014; 34: 673-679. doi: 10.1007/s40261-014-0218-x. EK II
    PubMedGoogle Scholar
  • 25 Koehler G, Treiber G, Wutte A. et al. Pharmacodynamics of the long- acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes Obes Metab 2014; 16: 57-62. doi: 10.1111/dom.12178. EK II
    CrossrefPubMedGoogle Scholar
  • 26 Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9: 648-659 doi: 10.1111/j.1463-1326.2007.00756.x. EK I
    CrossrefPubMedGoogle Scholar
  • 27 Becker RHA, Dahmen R, Bergmann K. et al. New insulin glargine 300 Units • mL-1 provides a more even activity profile and prolonged glyce- mic control at steady state compared with insulin glargine 100 Units • mL-1: The ELEMENT 1 study. Diabetes Care 2015; 38: 637-643. doi: 10.2337/dc14-0006. EK II
    PubMedGoogle Scholar
  • 28 Shiramoto M, Eto T, Irie S. et al. Single-dose new insulin glargine 300 U/ ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015; 17: 254-260 doi: 10.1111/dom.12415. EK II
    CrossrefPubMedGoogle Scholar
  • 29 Heise T, Pieber TR, Danne T. et al. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet 2017; 56: 551-559. doi: 10.1007/s40262- 017-0514-8. EK II
    CrossrefPubMedGoogle Scholar
  • 30 Heise T, Eckers U, Kanc K. et al. The pharmacokinetic and pharmacody- namic properties of different formulations of biphasic insulin aspart: A randomized, glucose clamp, crossover study. Diabetes Technol Ther 2008; 10: 479-485 doi: 10.1089/dia.2008.0019. EK II
    CrossrefPubMedGoogle Scholar
  • 31 Famulla S, Hovelmann U, Fischer A. et al. Insulin injection into lipohypertrophic tissue: Blunted and more variable insulin absorption and action and impaired postprandial glucose control. Diabetes Care 2016; 39: 1486-1492. doi: 10.2337/dc16-0610. EK II/LoE
    CrossrefPubMedGoogle Scholar
  • 32 Heise T, Weyer C, Serwas A. et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21: 800-803 doi: 10.2337/diacare.21.5.800. EC III
    CrossrefPubMedGoogle Scholar
  • 33 Rave K, Heinemann L, Puhl L. et al. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients. Diabetes Care 1999; 22: 865-866. EK III
    CrossrefPubMedGoogle Scholar
  • 34 Brunner M, Pieber T, Korsatko S. et al. The distinct prandial and basal pharmacodynamics of IDegAsp observed in younger adults are preserved in elderly subjects with type 1 diabetes. Drugs Aging 2015; 32: 583-590 doi: 10.1007/s40266-015-0272-y. EK II
    CrossrefPubMedGoogle Scholar
  • 35 Heise T, Nosek L, Roepstorff C. et al. Distinct prandial and basal glucose- lowering effects of insulin degludec/Insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus. Diabetes Ther 2014; 5 1: 255-265. doi: 10.1007/s13300-014-0070-2. EK II
    PubMedGoogle Scholar
  • 36 Institute for Quality and Efficiency in Health Care Short-acting insulin analogues for the treatment of diabetes mellitus type 1. Final report. Order A05-02 Version 1.0; 2007 EK Ia
    PubMed
  • 37 Institute for Quality and Efficiency in Health Care Long-acting insulin analogues for the treatment of diabetes mellitus type 1. Final report. Order A05-01. version 1.0; 2010. EK Ia
    PubMed
  • 38 Singh SR, Ahmad F, Lal A. et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180: 385-397 EK Ia
    CrossrefPubMedGoogle Scholar
  • 39 Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009; 11: 372-378 EK Ia
    PubMedGoogle Scholar
  • 40 Mullins P, Sharplin P, Yki-Jarvinen H. et al. Negative binomial meta-re- gression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29: 1607-1619 EK Ia
    CrossrefPubMedGoogle Scholar
  • 41 Ashwell SG, Bradley C, Stephens JW. et al. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008; 31: 1112-1117. EK Ib
    CrossrefPubMedGoogle Scholar
  • 42 Hermansen K, Fontaine P, Kukolja KK. et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629. EK Ib
    CrossrefPubMedGoogle Scholar
  • 43 Bühn S, Breuing J, Mathes T. et al. Evidence report on selected research assignments within the S3 guideline “Therapy of type 1 diabetes”. Witten/Herdecke: IFOM; Institute for Research in Operative Medicine (University of Witten/Herdecke); 2016
    CrossrefGoogle Scholar
  • 44 Fullerton B, Siebenhofer A, Jeitler K. et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev 2016; CD012161. doi: 10.1002/ 14651858.CD012161. EK Ia/LoE 1++
    PubMed
  • 45 Vardi M, Jacobson E, Nini A. et al. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev 2008; CD006297 EK Ia/LoE 1+
    PubMedGoogle Scholar
  • 46 Retnakaran R, Hochman J, DeVries JH. et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004; 27: 2590-2596 EK Ia
    CrossrefPubMedGoogle Scholar
  • 47 Fatourechi MM, Kudva YC, Murad MH. et al. Clinical review: Hypoglyce- mia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009; 94: 729-740 EK Ia
    CrossrefPubMedGoogle Scholar
  • 48 Jeitler K, Horvath K, Berghold A. et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: Systematic review and meta-analysis. Diabetologia 2008; 51: 941-951. EK Ia
    CrossrefPubMedGoogle Scholar
  • 49 Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: Meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25: 765-774. EK IIb
    CrossrefPubMedGoogle Scholar
  • 50 Bolli GB, Kerr D, Thomas R. et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: A randomized open parallel multicenter study. Diabetes Care 2009; 32: 1170-1176. EK Ib
    CrossrefPubMedGoogle Scholar
  • 51 Steineck I, Cederholm J, Eliasson B. et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18168 people with type 1 diabetes: Observational study. BMJ 2015; 350: h3234. EK IIb
    CrossrefPubMedGoogle Scholar
  • 52 Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: Quality of life associated with insulin pump use in type 1 diabetes. Diabet Med 2007; 24: 607-617. EK Ia
    CrossrefPubMedGoogle Scholar
  • 53 Hoogma RP, Hammond PJ, Gomis R. et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2006; 23: 141-147. EK Ib
    CrossrefPubMedGoogle Scholar
  • 54 Mukhopadhyay A, Farrell T, Fraser RB. et al. Continuous subcutaneous insulin infusion vs. intensive conventional insulin therapy in pregnant diabetic women: A systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007; 197: 447-456. EK Ia
    CrossrefPubMedGoogle Scholar
  • 55 Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2007; 3: CD005542. EK Ia
    PubMedGoogle Scholar
  • 56 Chen R, Ben-Haroush A, Weismann-Brenner A. et al. Level of glycemic control and pregnancy outcome in type 1 diabetes: A comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol 2007; 197: 404-405. EK IIb
    PubMedGoogle Scholar
  • 57 Cypryk K, Kosinski M, Kaminska P. et al. Diabetes control and pregnancy outcomes in women with type 1 diabetes treated during pregnancy with continuous subcutaneous insulin infusion or multiple daily insulin injections. Pol Arch Med Wewn 2008; 118: 339-344 EK IIb
    PubMedGoogle Scholar
  • 58 Gimenez M, Conget I, Nicolau J. et al. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. Acta Diabetol 2007; 44: 34-37. EK III
    CrossrefPubMedGoogle Scholar
  • 59 Alto WA, Meyer D, Schneid J. et al. Assuring the accuracy of home glucose monitoring. J Am Board Fam Pract 2002; 15: 1-6. EK III
    PubMedGoogle Scholar
  • 60 Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006; 295: 1688-1697. EK IV
    CrossrefPubMedGoogle Scholar
  • 61 German Medical Association, National Association of Statutory Health Insurance Physicians, Association of Scientific Medical Societies. National Care Guideline Diabetes - Structured Training Programs - Long Version. 1st Edition. Version 4: On the Internet: http://www. dm-schulung.versorgungsleitlinien.de; Version: 04.11.2017. EK IV
    PubMedGoogle Scholar
  • 62 Kulzer B, Albus C, Herpertz S. et al. Psychosocial and diabetes (Part 1). Diabetology and metabolism 2013; a 8: 198-242. doi: 10.1055/ s-0033-1335785. level IV
    PubMedGoogle Scholar
  • 63 Kulzer B, Albus C, Herpertz S. et al. Psychosocial and diabetes (Part 2). Diabetology and metabolism 2013; b 8: 292-324. doi: 10.1055/ s-0033-1335889. level IV
    PubMedGoogle Scholar
  • 64 Hermanns N, Kulzer B, Krichbaum M. Problem-specific patient training. Overview of an essential component of diabetes therapy. Diabetologist 2008; 4: 361-367 th level III
    PubMedGoogle Scholar
  • 65 American Diabetes Association. 14. Diabetes Care in the Hospital. Diabe- tes Care 2017; 40 (Suppl. 1) S120-S127. doi: 10.2337/dc17-S017. EK IV
    PubMedGoogle Scholar
  • 66 Chen HS, Wu TE, Jap TS. et al. Effects of health education on glycemic control during holiday time in patients with type 2 diabetes mellitus. Am J Manag Care 2008; 14: 45-51 st EK Ib/LoE
    PubMedGoogle Scholar
  • 67 Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Im Internet: http://guidelines.diabetes.ca/app_themes/cdacpg/resources/ cpg_2013_full_en.pdf; Stand: 23.07.2017. EK IV
    PubMed
  • 68 Graveling AJ, Frier BM. Hypoglycaemia: An overview. Prim Care Diabetes 2009; 3: 131-139 th level III
    CrossrefPubMedGoogle Scholar
  • 69 Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-3176 EK III
    CrossrefPubMedGoogle Scholar
  • 70 Deary IJ, Hepburn DA, MacLeod KM. et al. Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia 1993; 36.: 771-777. EK III/LoE 3
    CrossrefPubMedGoogle Scholar
  • 71 McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med 2001; 18: 690-705. EK III
    CrossrefPubMedGoogle Scholar
  • 72 Haak T, Kellerer M. German Diabetes Society. Diagnostics, therapy and follow-up of diabetes mellitus in children and adolescents. Mainz; Kirchheim: 2009. EK IV
    CrossrefGoogle Scholar
  • 73 Kitabchi AE, Umpierrez GE, Murphy MB. et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006; 29: 2739-2748 EK IV
    CrossrefPubMedGoogle Scholar
  • 74 Kitabchi AE, Umpierrez GE, Miles JM. et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32: 1335-1343. EK IV
    CrossrefPubMedGoogle Scholar
  • 75 Bull SV, Douglas IS, Foster M. et al. Mandatory protocol for treating adult patients with diabetic ketoacidosis decreases intensive care unit and hospital lengths of stay: Results of a nonrandomized trial. Crit Care Med 2007; 35: 41-46 EK IIb
    CrossrefPubMedGoogle Scholar
  • 76 Joint British Diabetes Societies for inpatient care The Management of Diabetic Ketoacidosis in Adults. Second Edition Update: September. 2013; Im Internet: http://www.diabetologists-abcd.org.uk/JBDS/ JBDS_IP_DKA_Adults_Revised.pdf; Stand: 23.09.2017. EK IV
    PubMed
  • 77 German Medical Association, National Association of Statutory Health Insurance Physicians, Association of Scientific Medical Societies National Care Guideline Type 2 Diabetes - Kidney Diseases in Adult Diabetes. Version Consultation 1.0; 2010. level IV
    PubMed
  • 78 German Medical Association, National Association of Statutory Health Insurance Physicians, Association of Scientific Medical Societies National guideline for the prevention and treatment of retinal complications associated with diabetes - Long version. 2nd edition. Version 2: On the Internet: http://www.netzhautkomplikationen.versorgungsleitlinien.de Status: 19.10.2017. EK IV
    PubMed
  • 79 German Medical Association, National Association of Statutory Health Insurance Physicians, Association of Scientific Medical Societies National care guideline Neuropathy in diabetes in adolescence. 2010; LEVEL IV
    PubMed
  • 80 German Medical Association, National Association of Statutory Health Insurance Physicians, Association of Scientific Medical Societies National Care Guideline Type 2 Diabetes - Prevention and Treatment Strategies for Fuβkomplikationen. Version. 2.8; 2006 EK IV
    PubMed
  • 81 German Medical Association, Association of Scientific Medical Societies, National Association of Statutory Health Insurance Physicians National guideline for kidney disease in adult diabetes. 2010; LEVEL IV
    PubMed